

Fast Facts

WF 1806 - Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study

Eligibility criteria

1. Older adults (age ≥ 60 y) with either
 - newly diagnosed metastatic CRC or
 - newly recognized metastatic recurrence of CRC greater than 1 year from completion of treatment for non-metastatic CRC
2. Planning to undergo 1st line 5-FU based chemotherapy (as monotherapy [as 5-FU alone or capecitabine] or in combination with oxaliplatin and/or irinotecan +/- biologics).
3. Estimated life expectancy ≥ 6 months.
4. Patients must be able to comprehend English or Spanish (for questionnaire completion).
5. Ability to understand and the willingness to sign a written informed consent document.
6. Patient eligibility is not dependent on BMI or weight. Patients with a significant ($\pm > 10\%$) body weight change in the previous 12 months are eligible for this study.

Exclusion Criteria

1. Patients enrolled on hospice
2. Prior systemic chemotherapy for metastatic colorectal cancer (acceptable if adjuvant chemotherapy completed ≥ 12 months prior to disease recurrence).
3. Patients may not be receiving any other investigational agents. (For clarity, participants on the Alliance A021703 trial are also eligible for this study.)
4. No untreated brain metastases. Patients with treated brain metastases are eligible.

Schema

